Last reviewed · How we verify
cetuximab IV — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
cetuximab IV (cetuximab IV) — Groupe Oncologie Radiotherapie Tete et Cou.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| cetuximab IV TARGET | cetuximab IV | Groupe Oncologie Radiotherapie Tete et Cou | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- cetuximab IV CI watch — RSS
- cetuximab IV CI watch — Atom
- cetuximab IV CI watch — JSON
- cetuximab IV alone — RSS
Cite this brief
Drug Landscape (2026). cetuximab IV — Competitive Intelligence Brief. https://druglandscape.com/ci/cetuximab-iv. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab